-
Blogs Categories
Blog Tags
.Delay in Quick Shot Testosterone Clinical Trials (1)
2017 Results (1)
2018 (1)
2018 Northwest Biotherapeutics presentation at ASCO (1)
2019 (1)
2020 (1)
2021 and 2022 (1)
2022 (1)
4-Antibody (2)
7th Annual Phacilitate Immunotherapy Forum (1)
A.P. Pharma Inc. (12)
AB generic to EpiPen approval (1)
AB rated generic to Byetta (3)
AB Rated Generic to EpiPen (12)
AB rated generic to EpiPen launch (1)
AB Rated Generic to Forteo (3)
AB rated generic to Imitrex (3)
AB Rated version of EpiPen (1)
AB rated version of sumatriptan (1)
ACTC (1)
Adam Feuerstein (8)
Adam Feuerstein blog on Portola (1)
Adam Feuerstein May 10 report on Northwest Biotherapeutics (2)
Addressable market for Palforzia (1)
adenovirus (1)
adult neural stem cells in ALS (1)
Advanced Cell Techology. ACTC (1)
Advaxis (3)
AdVise trial of brincidofovir (3)
ADXS (3)
Aerosurf (19)
Aerosurf Phase 2b proof of concept trial (1)
Afectair (1)
AGEN (26)
Agenus (31)
Agenus checkpoint modulators (1)
Agenus collaboration with Incyte (1)
Agenus development of checkpoint modulators (1)
Agenus development of neonantigen cancer vaccines (1)
Agenus Royalty deal with Oberlan Capital (1)
Aimmune (1)
AIMT (1)
AIS (1)
Alexion (1)
ALIM (9)
Alimera (11)
Alimera 2017 second quarter results (1)
Alimera Sciences (2)
Alimera third quarter results (1)
Alkermes (1)
ALKM (1)
Allogene (1)
Aloxi (1)
ALPMY (1)
ALS (9)
Alternating Tangential Flow Filtration (1)
ALXN (1)
AMAG (9)
AMAG divests Cord Blood Registry (1)
Amgen (6)
Amgen and omecamtiv mecarbil (1)
AMGN (2)
AminoMatrix (1)
AmniMatrix (1)
Amnioexcel (4)
Amniomatrix (2)
amyotrophic lateral sclerosis (1)
AncexXa PDUFA extended to May 4 (1)
andexamet (1)
AndexXa (2)
AndexXa addressable market (1)
AndexXa approval (1)
Andexxa launch (3)
Andexxa PDUFA date and launch (1)
Andexxa sequential sales drop in 4Q (1)
Antares (10)
Antares comments on Type A meeting with FDA (1)
Antares Pharma Inc. (83)
Antares Presentation at Jefferies (1)
Antares response to Complete Response Letter (1)
Antares Sales and Earnings Model (1)
Antares Sales and Earnings Projections through 2022 (1)
APF530 (1)
APPA (2)
APPA.OB (1)
approval of AB rated generic to EpiPen (1)
Aradigm (1)
ARDM (1)
ARGS (1)
Ashkan presentation on DCVax-L at ASCO 2022 (1)
Astellas (1)
ATF (1)
ATF Cell filtration systems (1)
Athersys (5)
Athersys stem cells for ARDS causd by COVIDD-19 (1)
ATHX (2)
atomic-ahf (2)
ATRS (49)
Auriclosene (2)
Autolus (1)
Awaiting release of top line data for phase 3 trial of DCVax-L (1)
Axi-Cel (1)
Axi-Cel (axicabtagene ciloleucel) (2)
AzaSite (1)
AzaSite Plus (2)
Battelle (1)
BENEFIT-ALS (7)
betrixaban (2)
betrixaban approval by FDA (1)
bevyexxa manufacturing issue (1)
Bevyxxa launch (1)
Bevyxxa launch and manufactruing issues (1)
Bill Ackman of Pershing Square (1)
Bio CEO (1)
BioDelivery Sciences International (2)
Bioequivalence study for Makena (1)
Biotech Showcase (1)
biotechnology (1)
biotechnology market corrections (1)
biotechnology stock manipulation (1)
blepharitis (1)
bluebird bio (1)
BMS-986094 (1)
BMY (9)
borrowing cost for short sellers (1)
brincidofovir (4)
Bristol-Myers Squibb (28)
BromSite (2)
CADX (10)
Caladrius (1)
cancer vaccine (1)
cancer vaccine trial failures (1)
cancer vaccines (1)
cancer vaccines for glioblastoma (1)
CAR_T products supported by Cryoport (1)
CAR-T (3)
CAR-T cells (3)
CAR-T drugs (1)
CAR-T Products (1)
CAR-T Therapy (3)
Catalyst Pharmaceutical Partners Inc. (2)
CBST (4)
CDX-011 (4)
CDX-1127 (4)
CDX-1135 (4)
Cede's role in illegal naked shorting (1)
ceftaroline (1)
Celgene (1)
Celldex (2)
Celldex Therapeutics (11)
cerdulatinib phase 2 trial in PTCL (1)
CHECKMATE-214 Interim Analysis (1)
checkpoint-027 clinical trial (1)
Checkpoint-568 clinical trial (1)
chemotherapy induced nausea and vomiting (1)
chimeric antigen receptor T-cells (1)
Chimerix (10)
Chinese ischemic stroke trial (1)
Citron Research (1)
CK-107 (4)
CK-107 in spinal muscular atrophy (2)
CK-2127107 (1)
CK2127107 (1)
CLBS (1)
CLDX (16)
Clinical data for Optune in glioblastoma (1)
Clinical hold on ROCKET trial (1)
clinical trial (1)
clinical trials (4)
CMRX (10)
Comparing Novocure and Northwest Biotherapeutics (1)
Comparison of three month data from JULIET trial with ZUMA-1 (1)
Corcept (1)
CORT (1)
cosmic-hf (2)
COSMIC-HF trial in heart failure (1)
CPXX (1)
CRL for ZS-9 (1)
CRSPR (1)
cryogenically shipped live cells (1)
Cryoport (41)
Cryoport 1Q (1)
Cryoport acquisition of CRYOPDP (1)
Cryoport acquistions of CryoPDP and MVE Biologics (1)
Cryoport Equity offering June 20 (1)
Cryoport invovlemnt in COVID vaccines (1)
Cryoport logistics services for CAR-T products (1)
Cryoport logistics support got CAR-T products (1)
Cryoport potential benefits from COVID-19 vaccines (1)
Cryoport pre-announcement of 4Q (1)
Cryoport Research Report August 2020 (1)
Cryoport sales from launch of Kymriah and Yescarta (1)
Cryoport sales model through 2024 (1)
Cryoport second quarter 2017 results (1)
Cryoport Second Quarter Results (1)
Cryoport support of CAR-T saless (1)
Cryoport support of cell therapy products (1)
Cryport and the Yescartsa launch (1)
CTL-019 (2)
CTL-019 (tisagenlecleucel-T) (2)
Cubicin (3)
Cubist (6)
CUR (31)
Curis Inc. (1)
CYDT (1)
CYRX (9)
cytk (59)
CytoDyn (1)
Cytokentics collaboration with Astellas (1)
Cytokientics (1)
Cytokinetics (71)
Cytoknetics (1)
Cytoknetics deal with Astellas (1)
cytomegalovirus (1)
cytomegalovirus infections (1)
daptomycin (2)
Data on 39 patients from phase 1 trial of DCVax Direct (1)
Davonex (1)
DazaSite (1)
dcvax direct (28)
DCVax Direct Phase 1 Trial at ASCO (1)
DCVax Direct Phase 1/2 trial (1)
DCVax-L (29)
DCVax-L and Right to Try law (2)
DCVax-L blinded phase 3 results (1)
DCVax-L data versus Optune (1)
DCVax-L interim results from phase 3 trial in glioblastoma (1)
DCVAX-L Phase 2 in colorectal cancer (1)
DCVax-L phase 3 in newly diagnosed glioblastoma (3)
DCVax-L Phase 3 results in glioblastoma (1)
DCVax-L Phase 3 screening halt (1)
DCVax-L phase 3 trial in glioblastoma (1)
DCVax-L Phase 3 trial in newly diagnosed glioblastoma (2)
DCVax-L survival tail in newly diagnosed glioblastoma (1)
DCVax-L Use of Historical Controls in Phase 3 (1)
Deaths in ROCKET trial in r/r Adult ALl (1)
Dendreon Corporation (21)
dendritic cell cancer vaccines (5)
dendrtic cell cancer vaccines (1)
DERMA Phase III (2)
Derma Sciences (10)
Detailed earning forecast for Antares (1)
Detailed sales and earnings forecast model for Portola through 2021 (1)
DexaSite (2)
Dificid (1)
Discovery Laboratories Inc (30)
Discovery Laboratories Inc. (1)
DME (1)
DNDN (2)
Dr. Eva Feldman (1)
Dr. Keyoumers Ashkan speaks on DCVax-L (1)
Dr. Linda Liau Speaks on DCVax-L (2)
DRRX (1)
DSC-127 (3)
DSCI (10)
DSCO (22)
Durect (1)
Dyax Corp. (1)
Eamonn Hobbs (3)
EAMS (1)
Early Access to Medicines Scheme (1)
Ebola treatments. Brincidofovir use against Ebola (1)
Eliquis (1)
engineered autologous T cells (1)
Epi-Pen (1)
EpiPen (4)
European Society of Cardiology (1)
Expanded collaboration with Astellas (1)
Failure of phase 2b trial of Aerosurf (1)
FDA (2)
FDA accepts NDA resubmission as complete (1)
FDA action on Xyosted regulatory review (2)
FDA AdCom action on Lipocine's Tlando (1)
FDA Oncologics Drug Advisory Committee Meeting on Novaris' tisgenlecleucel (1)
Feraheme (1)
fidoxomicin (1)
Financing (1)
FORTITUDE-ALS Trial Results (1)
Fusilev (2)
GAIN Act (1)
GALACTIC-HF phase 3 trial in advance heart failure (1)
GALACTIC-HF phase 3 trial of omecamtiv in advanced heart failure (1)
Galderma (1)
GE decides to manufacture Protin A (1)
Gene therapy (1)
German hospital exemption early access (3)
GERN (2)
Geron (2)
Gilead (2)
GLACTIC-HF study on omecamtiv mecarbil presentation at American Heart Association (1)
Glaxo (3)
glembatumumab (4)
glembutumamab (1)
glioblastoma (5)
granisetron (2)
GSK (2)
hematopoiectic cell transplants (1)
Heron Therapeutics (13)
HRTX (1)
HTC (1)
hyperkalemia (1)
ICT-107 (7)
illegal naked shorting by hedge funds (1)
Iluvien (8)
Iluvien in diabetic macular edema (1)
Immuno-oncology (2)
ImmunoCelluar Therapeutics (1)
ImmunoCellular (4)
ImmunoCellular Therapeutics LTD (17)
Impact on Antares of Makena SC approval (1)
Implication of MyoKardia acquisition for Cytokinetics (1)
IMUC (16)
IMUC. Senesco (1)
Inc. (24)
Incivo (1)
Industry news (1)
Inhibitex (1)
INO (1)
Inovio (2)
InSite Vision (10)
INSV (3)
INSV.OB (1)
Intermezzo (2)
Is omecamtiv mecarbil approvable (1)
JAMA peer reviewed article on DCVax-L (1)
JCAR-015 (1)
JCAR-015 clinical hold in Rocket trial (1)
JCAR-017 (1)
JCAR015 (1)
JNJ (1)
Johnson & Johnson (13)
JP Morgan (1)
JULIET trial (1)
July 12 AdCom Meeting for CTL-019 (1)
June 24th PDUFA date for betrixaban (1)
JUNO (8)
Juno and Kite CAR-T development programs (1)
KaloBios (2)
KBIO (2)
Kefzara (1)
key biotechnology platform technologies (2)
Keytruda (3)
KITE (19)
Kite October 18 (1)
Kite Pharma (11)
KL-4 (2)
KTE-C19 (6)
Kymriah (1)
Kymriah launch (1)
kyperkalemia (1)
launch of AB rated generic to EpiPen (1)
Launch of CAR-T products CTL-019 and Axi-Cel (1)
launch of subcu dosage form of Makena (1)
Launcj of Makena subcutaneous auto-injector (1)
lending stock to short sellers (1)
Lifting partial hold on phase 3 trial of DCVax-L (1)
Linda Powers (1)
linezolid (1)
LTD (1)
lucinactant (1)
MAGE A-3 (2)
MAGE-A3 (1)
Makena (4)
Makena launch and market opportunity (1)
Makena subcu dosage form launch (1)
Malaria (1)
Mallinckrodt (1)
managed care (1)
manufactruing issues with Bevyxxa (1)
manufacturing cost of DCVax-L (1)
Manuscript on blinded data from phase 3 trial of DCVax-L (1)
market and stock manipulation (1)
Marnix Boscg comments at 209 ASCO (1)
Martin Shkreli (1)
Medac (2)
Medac Pharma (1)
Medidur (1)
Medihoney (6)
Medivation Inc. (1)
MELA Sciences (1)
Merck (1)
Mesoblast (2)
mesoblast stem cells for ARDS caused by COVID-19 (1)
methotrexate (3)
methylated MGMT (1)
MNK (1)
MRK (1)
MultiStem (1)
MYL (1)
Mylan (1)
naked shorting (1)
NBIX (1)
NBS (1)
NBY (6)
Neil Woodford (1)
Neil Woodword (1)
NeoStem (1)
Neuralstem and Stem Cell patent litigation (1)
Neuralstem, Inc. (34)
Neurastem (1)
Neurocrine (1)
New York Academy of Science report on phase 3 trial of DCVax-L in glioblastoma (1)
Northwest Bioteheraepeutics. NWBO. ICT-107. DCVax-l (1)
Northwest Biotheraepeutics (1)
Northwest Biotherapeutics Board of Directors (2)
Northwest Biotherapeutics Inc (1)
Northwest Biotherapeutics Inc. (108)
Northwest Biotherapeutics Lawsuit against Citadel and seven market makers (1)
Northwest Biotherapeutics Sawston UK manufacturing facility (1)
Northwest Biotrherapeutics (1)
NovaBay (8)
Novartis (3)
Novocure (1)
NSI neural stem cells used to treat ALS (1)
NSI-189 (4)
NSI-189 in major depressive disorder (3)
NSI-566 (9)
NSI-566 neural stem cells in ALS (2)
NWBO (72)
NWBO. Northwest Biotherapeutics. ImmunoCellular (1)
NWBOD (1)
Ofirmev (8)
OHRP (2)
Omecamtiv (5)
omecamtiv in congestive heart failure (2)
omecamtiv mecarbil (18)
omecamtiv mecarbil GALACTIC-HF trial (1)
Omecamtiv mecarbil results in COSMIC-HF (1)
omecamtiv mercarbil in GALACTIC-HF (1)
Omecantiv mecarbil top line data from GALACTIC-HF (1)
omecsmtiv mecarbil in congestive heart failure (1)
OMED (1)
OncoSec Medical (1)
ondansetron (1)
Ondexxya EU conditional approval (1)
One Med Forum (1)
ONTX (1)
Opdivo (3)
Opdivo in first line non small cell lung cancer (1)
Opdivo misses endpoint in Checkpoint-26 (1)
OPUS (4)
OPUS Chromatography columns (2)
OPUS Disposable Chromatography Columns (1)
Orencia (2)
oritavancin (1)
Otrexuo (2)
otrexup (20)
Otrexup launch (2)
oxazolidinone (1)
Ozurdex (1)
Palforzia for desensitization of peanut allergy (1)
patiromer (4)
Paul Wotton (2)
PCT cell based manufacturing (1)
Pfizer Inc. (3)
Pharmasset (1)
Phase 1/2 Trial of DCVax Direct (1)
Phase 2 trial of NSI-566 neural stem celss (1)
Phase 2b trial of Aerosurf (1)
Phase 3 trial of DCVax-L in newly diagnosed glioblastoma (2)
Phase 3 trial of DCVax-L in newly diagnosed glioblastoma multiforme (1)
phase II (1)
Portola (25)
potential contribution to Antares profits from Makena auto-injector (1)
Potential reasons for Xyosted CRL (1)
President Trump's remarks on right to try (1)
Prophage (4)
Prophage G-100 (2)
Prophage therapeutic cancer vaccines (1)
Protein A (1)
Protein A ligand (1)
Provenge (2)
PSDV (9)
PSI-7977 (1)
pSivida (3)
pSivida Corp (7)
psoriasis (1)
PTLA (7)
Q3 Results (1)
QS 21 Stimulon vaccine adjuvant (1)
QS-21 Adjuvant (1)
QST (6)
QST testosterone replacement (1)
Rasuvo (2)
ReACT (1)
ReAct Trial (1)
Refuting Adam Feuerstein's misrepresentation that DCVax-L phase 3 Trial failed (1)
Regeneron's Kevzara could reduce mortality from COVID-19 (1)
REGN (1)
reldesemtiv sales potential (1)
Relypsa (14)
Relypsa takeover (1)
Repligen (19)
Repligen acquires Spectrum (1)
Repligen acquisition of Atoll (1)
respiratory distress syndrome (2)
Resubmission of AndexXa BLA (1)
Results from ZUMA-1 trial of KTE-C19 (1)
RGEN (13)
Richard Pearson (3)
Rigel (1)
RIGL (2)
Rindopepimut (10)
Rintega (1)
Rintega failure in phase 3 ACT IV trial (1)
RLYP (11)
Royalty deal with Royalty Partners on Omecamtiv (1)
RTS (1)
RYLP (2)
Ryoncil (1)
S (1)
Sales projections for Xyosted in 2020 (1)
San Francisco (1)
Sangamo (1)
Sanofi (1)
Santarus Inc. (10)
Sawston manufacturing facility of Northwest Biotherapeutics (1)
Senesco (2)
Servier and omecamtiv mecarbil (1)
SGMO (1)
Shire plc (1)
Short selling (1)
Sivextro (1)
Skin Substitutes (1)
smithonstocks (1)
SmithOnStocks Top Stock Picks for 2017 (1)
SNTI (3)
SNY (1)
Spectrum Pharmaceuticals Inc. (3)
Spoofing stock manipipulation (1)
Statistical analysis plan for DCVax-L phase 3 trial (2)
STEM (1)
stem cell treatment of ALS (2)
Stem Cells (1)
StemCells (1)
Steven Hawking (1)
stock manipulation by hedge funds (1)
Stock manipulation of Northwest Biotherapeutics (1)
stock manipulation scheme against Northwest Biotherapeutics (1)
Sub-cutaneous injection dosage form of Makena (1)
subcutaneous formulation of Makena (2)
Subcutaneous Makena launch (1)
Sufaxin (1)
SUPPRESS trial of brincidofovir (3)
Surfactant (1)
Surfaxin (8)
Surfaxin LS (2)
Surfxin (1)
Surviival Tail of DCVax-L in Newly Diagnosed Glioblastome (1)
suspension of screening in DCVax-L phase 3 trial (1)
Suspension of screening in DCVax-L trial (1)
SUSTAIN and SURPASS trials of brincidofovir (1)
Syvextro (1)
Targacept (1)
TCC-EZ (6)
ted (1)
tedizolid (6)
Tedizolod (1)
Teflaro (1)
testosterone replacement market (1)
Tethadur (2)
teva (2)
Teva launches AB generic to Imitrex (1)
tirasemetiv VITALITY-ALS trial (1)
tirasemtiv (24)
tirasemtiv in phase 3 VITALITY-ALS Trial (2)
tirasemtiv versus edaravone in ALD (1)
tirasmetiv (1)
Titan (1)
Tracking Xyosted Prescriptions (1)
Transcept Pharmaceuticals (14)
TRGT (1)
Trius CVR (1)
Trius Therapeutics (15)
TSPT (3)
TSRX (4)
TTPI (1)
UCBE (2)
Uncertainty about FDA approval of AndexXa (1)
Valtessa (1)
vancomycin (1)
varilumab (2)
varlilumab (3)
Veltassa (7)
Veltassa Launch (2)
Veltassa March 2016 results (1)
VGX-3100 (1)
ViroPharma Inc. (1)
VITALITY-ALS (3)
Vivus Inc. (3)
VRX (1)
Wall Street is Poised for Disruption (2)
Windtree licensing deal with Lee's Pharmacetical (1)
WINT (4)
wound dressing (1)
Xarelto (2)
Xyosted (1)
Xyosted approval (1)
Xyosted CRL (2)
Xyosted launch (4)
Xyosted prescription trends through September 20 (1)
Xyosted sales trends in 1Q (1)
Yervoy (1)
Yescarta (1)
Yescarta launch (1)
Yescarta sales projections (1)
ZS Pharma (4)
ZS-9 (8)
ZSPH (4)
ZUMA-1 (2)
ZUMA-1 interim results with KTE-C19 (1)
ZUMA-1 results (1)
ZUMA-1 trial (1)
Zytiga (1)
Zyvox (2)
